US Patent 8093220 Combination of an HDAC inhibitor and an antimetabolite

Patent 8093220 was granted and assigned to Novartis on January, 2012 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Novartis

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

8093220

Date of Patent

January 10, 2012

Patent Application Number

12516656

Date Filed

November 30, 2007

Patent Citations Received

‌

US Patent 11919839 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors

Patent Primary Examiner

‌

Shengjun Wang

Patent abstract

The invention relates to a combination which comprises:(a) a HDAI; and(b) an anti-metabolite,for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases, more specifically MDS or AML. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating MDS or AML, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8093220 Combination of an HDAC inhibitor and an antimetabolite

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API